Weekly Rundown: Small-Cap Stocks with Key Catalysts (July 7-11)

We're tracking fresh filings, notable headlines, and key updates from small-cap companies. This weekly recap is designed to keep you up to speed and in the know. Here are the top developments we’re watching for the week of July 7-11.

Companies with Key Catalysts This Week:

DC – S-K 1300 technical report for Richmond Hill to be released after market close on July 7; management webcast scheduled for July 8.

GIFT – On May 30, 2025, Giftify, Inc. formed a subsidiary, TakeOut7 Acquisition Corp., and entered into a merger agreement to acquire TakeOut7 Inc., a restaurant-focused digital marketing platform. Giftify will issue 350,000 restricted shares to TakeOut7 shareholders, making TakeOut7 a wholly owned subsidiary upon closing. The agreement includes an “Outside Date” of July 7, 2025, by which the deal must close or be terminated if certain conditions aren’t met, including material breaches by TakeOut7 that cannot be cured. Giftify cannot terminate the deal if its own actions prevent closing by that date.

LGPS – Ex-dividend date for $0.023/share cash dividend set for July 7; payment scheduled for August 5 if approved.

STTK – Participating in DR3/TL1A panel and 1-on-1 meetings at Leerink Partners Therapeutics Forum on July 8–9 in Boston.

RSLS – USPTO to issue new patent for intragastric balloon system on July 8, 2025; protection through at least Jan 2031.

XAGE – On June 24, 2025, amended merger agreement extended due diligence deadline to July 8, 2025; without mutual consent to extend, merger with 20/20 Biolabs will automatically terminate on that date.

IMAB – Phase 1b combo data for givastomig to be presented at ESMO GI 2025 on July 8; virtual investor event same day.

IFRX – Will attend Leerink Therapeutics Forum in Boston on July 8–9, 2025; 1-on-1 investor meetings scheduled.

MAIA – Two poster presentations on telomere-targeting therapies at FEBS Congress in Istanbul on July 7, 2025.

PCSA – CEO to host live investor webinar on pipeline strategy and milestones on July 9, 2025, at 4:15 p.m. ET.

LPCN – Virtual R&D event on July 9, 2025, at 11:00 a.m. ET focused on postpartum depression treatment.

CGTX – End-of-Phase 2 FDA meeting for Alzheimer’s drug zervimesine scheduled for July 9, 2025.

VVPR – Record date set for Caret Digital spin-off dividend (5:1 ratio) on July 9, 2025.

ONDS – Virtual Investor Day for Ondas Autonomous Systems unit to be held July 9, 2025.

NEHC – JV Texas Critical Data Centers signed LOI with major global AI cloud provider; progressing toward July 10, 2025, land closing for 250MW AI/HPC campus in Texas; next milestones include gas supply and grid interconnection updates.

ABAT – $6.75M property sale in Nevada expected to close on or before July 10, 2025.

ENTX / OPK – New OPK-88006 data to be presented at ENDO 2025 in San Francisco, July 12–15.

IMG – CIMG to host Appreciation Dinner in Shanghai on July 13, 2025, post-Huomao acquisition.

GRI – Interim 6-week biomarker data expected to be reported in July 2025.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.